Developer docs
API playgroundTry for free, no card

Search company profiles

Imanis Life Sciences

Full company profile

uuid000ago2

Namestring
Imanis Life Sciences
Legal namestring
Imanis Life Sciences
Websiteurl
imanislife.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Imanis Life Sciences is a privately held biotechnology company founded in 2012 in Rochester, Minnesota, by three Mayo Clinic professors — Drs. Stephen Russell, Kah-Whye Peng, and Michael O'Connor — who built Mayo's virus and gene therapy program and originated the NIS reporter gene imaging technology. The company operates as a hybrid research tools and contract research organization (CRO), serving academic researchers, biopharmaceutical companies, and other CROs working on cell therapy, gene therapy, oncolytic virotherapy, regenerative medicine, and vaccine development. Its mission is to enable widespread adoption of non-invasive imaging technologies in preclinical therapeutic research.

The company's product portfolio centers on a lentiviral vector platform built around two proprietary technology franchises. The Cellective Targeting System uses programmable G-fusogen adapters and the G-Link CD3 protein to retarget VSV-G pseudotyped lentiviral vectors to specific cell receptors (notably CD3+ T cells), enabling precision cell engineering for cell therapy developers. A second franchise comprises reporter gene tools — firefly luciferase, fluorescent proteins (eGFP, iRFP), nuclear reporters (NIS, hNET, hSSTR2, HSVTK, hDRD2), and tyrosinase — delivered as ready-to-use lentiviral vectors and as over 20 validated stable tumor and tumor-antigen cell lines (4T1, A20, A375, B16F10, BCMA, CD19, CD20, EGFR, and others) used for in vivo biodistribution and immune-oncology imaging studies.

Revenue is generated through three streams: (1) catalog product sales of cell lines, lentiviral vectors, AAVs, and targeting reagents priced from $245 to $6,875 per unit; (2) custom product generation services for cell lines, lentiviral vectors, and AAVs; and (3) contract research and assay development/validation services spanning biodistribution, immunogenicity, pharmacokinetics, neutralizing antibody assays, Luminex cytokine profiling, immunophenotyping, and ELISPOT. Sales are conducted directly via a Shopify e-commerce website, email purchase orders, and phone, with global dry-ice shipping and a Material Transfer Agreement-based licensing model that restricts use to internal research. Named customers include Mayo Clinic, Northwestern University, Biogen, and Istituto Scientifico Romagnolo, with marquee use cases supporting publications in journals including Science Translational Medicine.

Short descriptiontext

Imanis Life Sciences is a Rochester, MN-based biotechnology company and CRO that provides lentiviral vector platforms, reporter gene cell lines, and contract research services to academic and biopharmaceutical developers of cell therapies, gene therapies, oncolytic virotherapies, and vaccines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersRochester, United States
HQ citystring
Rochester
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lentiviral vectors, reporter gene cell lines, oncolytic virotherapy research, cell engineering services, preclinical contract research
Industry2 codes
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biotechnology Research Products & Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Research Products
TypeOne Time License
Description

Sale of catalog products including stable cell lines, lentiviral vectors, AAVs, and targeting reagents. Products are sold for internal research use only under Material Transfer Agreement.

imanislife.com
2Custom Products
TypeOne Time License
Description

Custom generation of cell lines, lentiviral vectors, and AAVs to customer specifications. Generated by experienced scientists with same quality control as catalog products.

imanislife.com
3Contract Research Services
TypeProfessional Services
Description

Scientific contract research for development of oncolytic viruses, gene and cell therapies, regenerative medicines, and vaccines. Includes discovery projects, therapy development, and pre-clinical studies.

imanislife.com
4Assay Development & Validation
TypeProfessional Services
Description

Custom assay development and validation services including biodistribution, immunogenicity, pharmacokinetics, biomarker assays, and immunoassay services from discovery through clinical phases.

imanislife.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Stable Cell Lines - Reporter Gene
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Reporter gene cell lines ranging from $1,500 to $3,000 depending on cell type and reporter configuration. Single reporter lines start at $1,500, dual reporter lines at $2,100-$3,000.

imanislife.com
2Lentiviral Vectors and Plasmids
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Lentiviral vectors starting at $245. Available as standard titer (1x10^7 TU/mL) or concentrated (1x10^8 to 1x10^9 TU/mL).

imanislife.com
3G-Link CD3 Adapter Protein
ModelUnit PricingBilling cadencePay-as-you-go
Notes

G-Link CD3: $895 for 20 µg (enough to retarget 5x10^9 LV particles).

imanislife.com
4Cellective LV Targeting System
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Cellective LV CD3 Targeting Kits: Small $1,090, Medium $2,750, Large $6,875. Packaging Mix: Small $595, Medium $1,500, Large $3,750. CD3 Targeting Adapter: Small $495, Medium $1,250, Large $3,125.

imanislife.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Cellective
Description

Advanced lentiviral vector (LV) delivery platform enabling user-defined cell transduction for precision targeting of cells including CD3+ T cells.

imanislife.com
+1 more record
Core offering1 text field

Imanis Life Sciences manufactures and sells catalog and custom lentiviral vectors, reporter gene cell lines, and targeting reagents for preclinical oncology, gene therapy, and cell therapy research. The company also operates as a contract research organization (CRO), offering assay development and validation services alongside custom and contract research programs for oncolytic virotherapy, gene and cell therapies, regenerative medicines, and vaccines.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Imanis Life Sciences offers a unified portfolio of products and services for preclinical oncology and immune-oncology research. The core product line centers on the Cellective Targeting System and G-Link CD3, which are lentiviral vector-based platforms for precision cell transduction and T cell targeting. Supporting these are two main product categories: (1) Reporter Gene Lentiviral Vectors encoding optical reporters (Firefly Luciferase, Fluorescent Proteins, iRFP, Tyrosinase) and nuclear reporters (NIS, Nuclear Reporters), and (2) Reporter Gene Cell Lines encompassing over 20 tumor model cell lines including 4T1, A20, A375, A549, B16F10, C1498, CT26.WT, HCT116, HT1080, K562, LL/2, Nalm6, PC3, Raji, RPMI-8226, U266B1, as well as Tumor Antigen Cell Lines (BCMA, CD19, CD20, EGFR) for immunotherapy research. These cell lines and vectors are complemented by three service offerings: Custom Products (custom cell lines, lentiviral vectors, and AAVs), Assay Development & Validation (biodistribution, immunogenicity, pharmacokinetics, biomarker assays), and Contract Research (for oncolytic viruses, gene/cell therapies, regenerative medicines, and vaccines). The portfolio enables researchers to track cell and virus biodistribution in vivo through various imaging modalities.

Product and service7 records
1Reporter Gene Cell Lines
CategoryReporter Gene Cell Lines
Description

Stable tumor cell lines constitutively expressing reporter genes (firefly luciferase, eGFP, iRFP, NIS) for in vitro and in vivo imaging applications, including human xenograft models and mouse syngeneic models. Sold to academic and industry researchers for oncology and immune-oncology research.

2Reporter Gene Lentiviral Vectors
CategoryLentiviral Vectors
Description

Self-inactivating second-generation VSV-G pseudotyped lentiviral vectors encoding optical, fluorescent, near-infrared, and nuclear reporter genes for transduction across diverse cell types including primary cells. Sold to researchers for cell engineering and imaging studies.

3Cellective Targeting System
CategoryTargeting Reagents
Description

Proprietary lentiviral vector delivery platform with programmable G-fusogen technology and targeting adapters for precision transduction of specific cell types such as CD3+ T cells. Sold as kits (Small, Medium, Large) to cell therapy researchers.

4G-Link CD3 Adapter Protein
CategoryTargeting Reagents
Description

Adapter protein that binds to wild-type VSV-G on lentiviral vector surface and includes a trimerizing linker for high-avidity attachment to CD3 receptors on T cells. Sold to researchers developing CAR-T and T cell therapies.

5Custom Products
CategoryCustom Reagent Services
Description

Bespoke generation of cell lines, lentiviral vectors, and AAVs to customer specifications, with same quality control as catalog products. Service is targeted at researchers needing tailored reagents not available off-the-shelf.

6Assay Development & Validation
CategoryContract Research Services
Description

Bioanalytical testing services including molecular-based biodistribution assays, ligand-binding assays, cell-based neutralizing antibody assays, Luminex cytokine profiling, immunophenotyping, and ELISPOT T cell assays. Performed in accordance with FDA guidance for preclinical and clinical-stage programs.

7Contract Research
CategoryContract Research Services
Description

Scientific contract research for development of oncolytic viruses, gene and cell therapies, regenerative medicines, and vaccines, including discovery projects, therapy development, and preclinical studies. Provided to biopharmaceutical and academic researchers.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

A leading provider of custom lentiviral vectors, AAVs, and viral vector design services for gene and cell therapy research. Direct overlap with Imanis's lentiviral vector and custom vector service lines.

TypeDirect peer
Description

Specializes in recombinant cell lines, viral vectors, and assay services for cell therapy, gene therapy, and immuno-oncology research—directly overlapping with Imanis's reporter cell lines, vectors, and assay development offerings.

TypeDirect peer
Description

Supplies viral vectors, lentiviral particles, cell-based assays, and reporter cell lines for life science research—comparable product mix across lentiviral tools and assay reagents.

TypeDirect peer
Description

Research reagent marketplace partnering with academic labs to distribute specialized cell lines, antibodies, and viral tools—a comparable niche model for distributing unique research reagents developed in academic settings.

TypeDirect peer
Description

Develops transfection reagents and lentiviral vector packaging products for cell and gene therapy research—overlapping with Imanis's VSV-G pseudotyped lentiviral vector and viral delivery offerings.

TypeBroad incumbent
Description

Large life science services and products provider offering gene synthesis, lentiviral vectors, custom cell lines, and preclinical CRO services—a broader incumbent operating across all of Imanis's service categories.

TypeBroad incumbent
Description

Global CRO and life science tools provider with cell and gene therapy services and acquired lentiviral vector capabilities (via Vigene)—a much larger incumbent competing for similar biotech and academic customers.

TypeBroad incumbent
Description

Dominant life science tools company offering lentiviral production services, cell lines, and reporter gene assays—competes with Imanis across catalog reagents and custom services as part of a much broader portfolio.

TypeEmerging player
Description

Emerging gene therapy services and platform company focused on next-generation delivery and manufacturing—adjacent emerging competitor in the cell/gene therapy tools and services space.

TypeBroad incumbent
Description

Provides in vivo imaging reagents and bioluminescent/fluorescent reporter tools used alongside Imanis products in preclinical oncology research—comparable in the imaging-reporter niche as a broader tools provider.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imanis Life Sciences

Biotechnology Research Products & Servicesimanislife.com

Imanis Life Sciences is a Rochester, MN-based biotechnology company and CRO that provides lentiviral vector platforms, reporter gene cell lines, and contract research services to academic and biopharmaceutical developers of cell therapies, gene therapies, oncolytic virotherapies, and vaccines.

What Imanis Life Sciences does

Imanis Life Sciences is a privately held biotechnology company founded in 2012 in Rochester, Minnesota, by three Mayo Clinic professors — Drs. Stephen Russell, Kah-Whye Peng, and Michael O'Connor — who built Mayo's virus and gene therapy program and originated the NIS reporter gene imaging technology. The company operates as a hybrid research tools and contract research organization (CRO), serving academic researchers, biopharmaceutical companies, and other CROs working on cell therapy, gene therapy, oncolytic virotherapy, regenerative medicine, and vaccine development. Its mission is to enable widespread adoption of non-invasive imaging technologies in preclinical therapeutic research.

The company's product portfolio centers on a lentiviral vector platform built around two proprietary technology franchises. The Cellective Targeting System uses programmable G-fusogen adapters and the G-Link CD3 protein to retarget VSV-G pseudotyped lentiviral vectors to specific cell receptors (notably CD3+ T cells), enabling precision cell engineering for cell therapy developers. A second franchise comprises reporter gene tools — firefly luciferase, fluorescent proteins (eGFP, iRFP), nuclear reporters (NIS, hNET, hSSTR2, HSVTK, hDRD2), and tyrosinase — delivered as ready-to-use lentiviral vectors and as over 20 validated stable tumor and tumor-antigen cell lines (4T1, A20, A375, B16F10, BCMA, CD19, CD20, EGFR, and others) used for in vivo biodistribution and immune-oncology imaging studies.

Revenue is generated through three streams: (1) catalog product sales of cell lines, lentiviral vectors, AAVs, and targeting reagents priced from $245 to $6,875 per unit; (2) custom product generation services for cell lines, lentiviral vectors, and AAVs; and (3) contract research and assay development/validation services spanning biodistribution, immunogenicity, pharmacokinetics, neutralizing antibody assays, Luminex cytokine profiling, immunophenotyping, and ELISPOT. Sales are conducted directly via a Shopify e-commerce website, email purchase orders, and phone, with global dry-ice shipping and a Material Transfer Agreement-based licensing model that restricts use to internal research. Named customers include Mayo Clinic, Northwestern University, Biogen, and Istituto Scientifico Romagnolo, with marquee use cases supporting publications in journals including Science Translational Medicine.

Imanis Life Sciences firmographics

Firmographics
Name
Imanis Life Sciences
Legal name
Imanis Life Sciences
Website
https://imanislife.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Imanis Life Sciences is a Rochester, MN-based biotechnology company and CRO that provides lentiviral vector platforms, reporter gene cell lines, and contract research services to academic and biopharmaceutical developers of cell therapies, gene therapies, oncolytic virotherapies, and vaccines.
Ownership category
akta.pro rank

Imanis Life Sciences industry classification

Industry
Product category
Biotechnology Research Products & Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAACAB
Lentiviral Vector Gene Therapy Developers
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAGAAAL
Specialty Therapeutic-Area CROs (e.g., oncology/rare disease)

Keywords

  • Lentiviral vectors
  • Reporter gene cell lines
  • Oncolytic virotherapy research
  • Cell engineering services
  • Preclinical contract research

Where Imanis Life Sciences is headquartered

Location

Headquarters

HQ city
Rochester
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Imanis Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Research Products: Sale of catalog products including stable cell lines, lentiviral vectors, AAVs, and targeting reagents. Products are sold for internal research use only under Material Transfer Agreement.
  2. Custom Products: Custom generation of cell lines, lentiviral vectors, and AAVs to customer specifications. Generated by experienced scientists with same quality control as catalog products.
  3. Contract Research Services: Scientific contract research for development of oncolytic viruses, gene and cell therapies, regenerative medicines, and vaccines. Includes discovery projects, therapy development, and pre-clinical studies.
  4. Assay Development & Validation: Custom assay development and validation services including biodistribution, immunogenicity, pharmacokinetics, biomarker assays, and immunoassay services from discovery through clinical phases.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStable Cell Lines - Reporter Gene
Unit PricingPay-as-you-goLentiviral Vectors and Plasmids
Unit PricingPay-as-you-goG-Link CD3 Adapter Protein
Unit PricingPay-as-you-goCellective LV Targeting System

Go-to-market motion1 record

Distribution channels4 records

Marketing channels8 records

Imanis Life Sciences product offering

Product offering

Core offering

Imanis Life Sciences manufactures and sells catalog and custom lentiviral vectors, reporter gene cell lines, and targeting reagents for preclinical oncology, gene therapy, and cell therapy research. The company also operates as a contract research organization (CRO), offering assay development and validation services alongside custom and contract research programs for oncolytic virotherapy, gene and cell therapies, regenerative medicines, and vaccines.

Product overview

Imanis Life Sciences offers a unified portfolio of products and services for preclinical oncology and immune-oncology research. The core product line centers on the Cellective Targeting System and G-Link CD3, which are lentiviral vector-based platforms for precision cell transduction and T cell targeting. Supporting these are two main product categories: (1) Reporter Gene Lentiviral Vectors encoding optical reporters (Firefly Luciferase, Fluorescent Proteins, iRFP, Tyrosinase) and nuclear reporters (NIS, Nuclear Reporters), and (2) Reporter Gene Cell Lines encompassing over 20 tumor model cell lines including 4T1, A20, A375, A549, B16F10, C1498, CT26.WT, HCT116, HT1080, K562, LL/2, Nalm6, PC3, Raji, RPMI-8226, U266B1, as well as Tumor Antigen Cell Lines (BCMA, CD19, CD20, EGFR) for immunotherapy research. These cell lines and vectors are complemented by three service offerings: Custom Products (custom cell lines, lentiviral vectors, and AAVs), Assay Development & Validation (biodistribution, immunogenicity, pharmacokinetics, biomarker assays), and Contract Research (for oncolytic viruses, gene/cell therapies, regenerative medicines, and vaccines). The portfolio enables researchers to track cell and virus biodistribution in vivo through various imaging modalities.

Differentiator

Problem solved

Functional benefit

Brands

  • Cellective: Advanced lentiviral vector (LV) delivery platform enabling user-defined cell transduction for precision targeting of cells including CD3+ T cells.
  • G-Link CD3

Products and services

  • Reporter Gene Cell Lines Stable tumor cell lines constitutively expressing reporter genes (firefly luciferase, eGFP, iRFP, NIS) for in vitro and in vivo imaging applications, including human xenograft models and mouse syngeneic models. Sold to academic and industry researchers for oncology and immune-oncology research.
  • Reporter Gene Lentiviral Vectors Self-inactivating second-generation VSV-G pseudotyped lentiviral vectors encoding optical, fluorescent, near-infrared, and nuclear reporter genes for transduction across diverse cell types including primary cells. Sold to researchers for cell engineering and imaging studies.
  • Cellective Targeting System Proprietary lentiviral vector delivery platform with programmable G-fusogen technology and targeting adapters for precision transduction of specific cell types such as CD3+ T cells. Sold as kits (Small, Medium, Large) to cell therapy researchers.
  • G-Link CD3 Adapter Protein Adapter protein that binds to wild-type VSV-G on lentiviral vector surface and includes a trimerizing linker for high-avidity attachment to CD3 receptors on T cells. Sold to researchers developing CAR-T and T cell therapies.
  • Custom Products Bespoke generation of cell lines, lentiviral vectors, and AAVs to customer specifications, with same quality control as catalog products. Service is targeted at researchers needing tailored reagents not available off-the-shelf.
  • Assay Development & Validation Bioanalytical testing services including molecular-based biodistribution assays, ligand-binding assays, cell-based neutralizing antibody assays, Luminex cytokine profiling, immunophenotyping, and ELISPOT T cell assays. Performed in accordance with FDA guidance for preclinical and clinical-stage programs.
  • Contract Research Scientific contract research for development of oncolytic viruses, gene and cell therapies, regenerative medicines, and vaccines, including discovery projects, therapy development, and preclinical studies. Provided to biopharmaceutical and academic researchers.

Companies that use Imanis Life Sciences

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Imanis Life Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Imanis Life Sciences partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Imanis Life Sciences competitors and assessment

Company assessment

Direct peers

  • VectorBuilder: A leading provider of custom lentiviral vectors, AAVs, and viral vector design services for gene and cell therapy research. Direct overlap with Imanis's lentiviral vector and custom vector service lines.
  • BPS Bioscience: Specializes in recombinant cell lines, viral vectors, and assay services for cell therapy, gene therapy, and immuno-oncology research—directly overlapping with Imanis's reporter cell lines, vectors, and assay development offerings.
  • Cell Biolabs: Supplies viral vectors, lentiviral particles, cell-based assays, and reporter cell lines for life science research—comparable product mix across lentiviral tools and assay reagents.
  • Kerafast: Research reagent marketplace partnering with academic labs to distribute specialized cell lines, antibodies, and viral tools—a comparable niche model for distributing unique research reagents developed in academic settings.
  • Mirus Bio: Develops transfection reagents and lentiviral vector packaging products for cell and gene therapy research—overlapping with Imanis's VSV-G pseudotyped lentiviral vector and viral delivery offerings.

Broad incumbents

  • GenScript: Large life science services and products provider offering gene synthesis, lentiviral vectors, custom cell lines, and preclinical CRO services—a broader incumbent operating across all of Imanis's service categories.
  • Charles River Laboratories: Global CRO and life science tools provider with cell and gene therapy services and acquired lentiviral vector capabilities (via Vigene)—a much larger incumbent competing for similar biotech and academic customers.
  • Thermo Fisher Scientific: Dominant life science tools company offering lentiviral production services, cell lines, and reporter gene assays—competes with Imanis across catalog reagents and custom services as part of a much broader portfolio.
  • Revvity (formerly PerkinElmer Life Sciences): Provides in vivo imaging reagents and bioluminescent/fluorescent reporter tools used alongside Imanis products in preclinical oncology research—comparable in the imaging-reporter niche as a broader tools provider.

Emerging players

  • Codex Bio: Emerging gene therapy services and platform company focused on next-generation delivery and manufacturing—adjacent emerging competitor in the cell/gene therapy tools and services space.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Imanis Life Sciences social profiles

Digital presence

Imanis Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imanis Life Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Imanis Life Sciences funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imanis Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imanis Life Sciences

What does Imanis Life Sciences do?

Imanis Life Sciences manufactures and sells catalog and custom lentiviral vectors, reporter gene cell lines, and targeting reagents for preclinical oncology, gene therapy, and cell therapy research. The company also operates as a contract research organization (CRO), offering assay development and validation services alongside custom and contract research programs for oncolytic virotherapy, gene and cell therapies, regenerative medicines, and vaccines.

Is Imanis Life Sciences a public or private company?

Imanis Life Sciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Imanis Life Sciences founded?

Imanis Life Sciences was founded in 2012. It employs 51 to 100 people.

Where is Imanis Life Sciences based?

Imanis Life Sciences is headquartered in Rochester, United States, in the North America region.

How does Imanis Life Sciences make money?

Four revenue lines are on record. Research Products are the primary driver. The others are custom Products, contract Research Services and assay Development & Validation.

Who are Imanis Life Sciences's main competitors?

Direct peers on record are VectorBuilder, BPS Bioscience, Cell Biolabs, Kerafast and Mirus Bio. Broad incumbents are GenScript, Charles River Laboratories, Thermo Fisher Scientific and Revvity (formerly PerkinElmer Life Sciences). Codex Bio is listed as an emerging player.

Does Imanis Life Sciences have an API?

No public API is recorded for Imanis Life Sciences.

What industry is Imanis Life Sciences in?

Imanis Life Sciences's product category is Biotechnology Research Products & Services. Its primary akta.pro industry code is HLAAACAB, Lentiviral Vector Gene Therapy Developers, with a secondary code of HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals